Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. World Most cancers Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 nations. CA: A Most cancers J Clin. 2021;71:209–49.
Kroep S, Lansdorp-Vogelaar I, Rubenstein JH, Lemmens VEPP, van Heijningen EB, Aragonés N, et al. Evaluating tendencies in esophageal adenocarcinoma incidence and way of life elements between america, Spain, and The Netherlands. Am J Gastroenterol. 2014;109:336–44.
Spechler SJ. Barrett esophagus and danger of esophageal most cancers: a scientific evaluation. J Am Med Assoc. 2013;310:627–36.
Kambhampati S, Tieu AH, Luber B, Wang H, Meltzer SJ. Threat elements for development of Barrett’s esophagus to excessive grade dysplasia and esophageal adenocarcinoma. Sci Rep. 2020;10:4899.
Then EO, Lopez M, Saleem S, Gayam V, Sunkara T, Culliford A, et al. Esophageal most cancers: an up to date surveillance epidemiology and finish outcomes database evaluation. World J Oncol. 2020;11:55–64.
Fan Y, Yuan J-M, Wang R, Gao Y-T, Yu MC. Alcohol, tobacco and weight loss plan in relation to esophageal most cancers: The Shanghai Cohort Examine. Nutr Most cancers. 2008;60:354–63.
Alexandre L, Lengthy E, Beales IL. Pathophysiological mechanisms linking weight problems and esophageal adenocarcinoma. World J Gastrointest Pathophysiol. 2014;5:534–49.
Yu X, Chen J, Jiang W, Zhang D. Alcohol, alcoholic drinks and danger of esophageal most cancers by histological sort: a dose-response meta-analysis of observational research. Alcohol Alcohol. 2020;55:457–67.
Chang JT, Katzka DA. Gastroesophageal reflux illness, Barrett esophagus, and esophageal adenocarcinoma. Arch Intern Med. 2004;164:1482–8.
Deshpande NP, Riordan SM, Castaño-RodrÃguez N, Wilkins MR, Kaakoush NO. Signatures inside the esophageal microbiome are related to host genetics, age, and illness. Microbiome. 2018;6:227.
Bhat S, Coleman HG, Yousef F, Johnston BT, McManus DT, Gavin AT, et al. Threat of malignant development in Barrett’s esophagus sufferers: outcomes from a big population-based examine. JNCI: J Natl Most cancers Inst. 2011;103:1049–57.
Chen X, Yang CS. Esophageal adenocarcinoma: a evaluation and views on the mechanism of carcinogenesis and chemoprevention. Carcinogenesis. 2001;22:1119–29.
Kaz AM, Grady WM, Stachler MD, Bass AJ. Genetic and epigenetic alterations in Barrett’s esophagus and esophageal adenocarcinoma. Gastroenterol Clin North Am. 2015;44:473–89.
Ajayi TA, Cantrell S, Spann A, Garman KS. Barrett’s esophagus and esophageal most cancers: hyperlinks to microbes and the microbiome. PLoS Pathog. 2018;14:e1007384.
Lv J, Guo L, Liu J-J, Zhao H-P, Zhang J, Wang J-H. Alteration of the esophageal microbiota in Barrett’s esophagus and esophageal adenocarcinoma. World J Gastroenterol. 2019;25:2149–61.
Armstrong H, Bording-Jorgensen M, Dijk S, Wine E. The complicated interaction between power irritation, the microbiome, and most cancers: understanding illness development and what we will do to stop it. Cancers. 2018;10:83.
Quante M, Graham TA, Jansen M. Insights into the pathophysiology of esophageal adenocarcinoma. Gastroenterology. 2018;154:406–20.
Zheng D, Liwinski T, Elinav E. Interplay between microbiota and immunity in well being and illness. Cell Res. 2020;30:492–506.
Smet A, Kupcinskas J, Hyperlink A, Maintain GL, Bornschein J. The position of microbiota in gastrointestinal most cancers and most cancers therapy: likelihood or curse? Cell Mol Gastroenterol Hepatol. 2022;13:857–74.
Snider EJ, Compres G, Freedberg DE, Khiabanian H, Nobel YR, Stump S, et al. Alterations to the esophageal microbiome related to development from Barrett’s esophagus to esophageal adenocarcinoma. Most cancers Epidemiol, Biomark Prev. 2019;28:1687–93.
Elliott DRF, Walker AW, O’Donovan M, Parkhill J, Fitzgerald RC. A non-endoscopic machine to pattern the oesophageal microbiota: a case-control examine. lancet Gastroenterol Hepatol. 2017;2:32–42.
Lopetuso LR, Severgnini M, Pecere S, Ponziani FR, Boskoski I, Larghi A, et al. Esophageal microbiome signature in sufferers with Barrett’s esophagus and esophageal adenocarcinoma. PLoS ONE. 2020;15:e0231789.
Peter S, Pendergraft A, VanDerPol W, Wilcox CM, Kyanam Kabir Baig KR, Morrow C, et al. Mucosa-associated microbiota in Barrett’s esophagus, dysplasia, and esophageal adenocarcinoma differ equally in contrast with wholesome controls. Clin Transl Gastroenterol. 2020;11:e00199–e00199.
Gall A, Fero J, McCoy C, Claywell BC, Sanchez CA, Blount PL, et al. Bacterial composition of the human higher gastrointestinal tract microbiome is dynamic and related to genomic instability in a Barrett’s esophagus cohort. PLoS ONE. 2015;10:e0129055.
Peters BA, Wu J, Pei Z, Yang L, Purdue MP, Freedman ND, et al. Oral microbiome composition displays potential danger for esophageal cancers. Most cancers Res. 2017;77:6777–87.
Poore GD, Kopylova E, Zhu Q, Carpenter C, Fraraccio S, Wandro S, et al. Microbiome analyses of blood and tissues recommend most cancers diagnostic strategy. Nature. 2020;579:567–74.
Zozaya-Valdes E, Wong SQ, Raleigh J, Hatzimihalis A, Ftouni S, Papenfuss AT, et al. Detection of cell-free microbial DNA utilizing a contaminant-controlled evaluation framework. Genome Biol. 2021;22:187.
Dong Z, Chen B, Pan H, Wang D, Liu M, Yang Y, et al. Detection of microbial 16S rRNA gene within the serum of sufferers with gastric most cancers. Entrance Oncol. 2019;9:608.
Xiao Q, Lu W, Kong X, Shao YW, Hu Y, Wang A, et al. Alterations of circulating bacterial DNA in colorectal most cancers and adenoma: a proof-of-concept examine. Most cancers Lett. 2021;499:201–8.
Chin RI, Chen Ok, Usmani A, Chua C, Harris PK, Binkley MS, et al. Detection of strong tumor molecular residual illness (MRD) utilizing circulating tumor DNA (ctDNA). Mol analysis Ther. 2019;23:311–31.
Adlung L, Elinav E, Greten TF, Korangy F. Microbiome genomics for most cancers prediction. Nat Most cancers. 2020;1:379–81.
Martin M. Cutadapt removes adapter sequences from high-throughput sequencing reads. EMBnet J. 2011;17:10–12.
Al-Ghalith GA, Hillmann B, Ang Ok, Shields-Cutler R, Knights D. SHI7 is a self-learning pipeline for multipurpose short-read DNA high quality management. mSystems 2018;3: e00202-00217.
O’Leary NA, Wright MW, Brister JR, Ciufo S, Haddad D, McVeigh R, et al. Reference sequence (RefSeq) database at NCBI: present standing, taxonomic growth, and purposeful annotation. Nucleic Acids Res. 2016;44:D733–745.
Beghini F, McIver LJ, Blanco-MÃguez A, Dubois L, Asnicar F, Maharjan S, et al. Integrating taxonomic, purposeful, and strain-level profiling of numerous microbial communities with bioBakery 3. eLife. 2021;10:e65088.
Bolger AM, Lohse M, Usadel B. Trimmomatic: a versatile trimmer for Illumina sequence knowledge. Bioinformatics. 2014;30:2114–20.
Could M, Abrams JA. Rising insights into the esophageal microbiome. Curr Deal with Choices Gastroenterol. 2018;16:72–85.
Choi HJ, Kim J, Do KH, Park S-H, Moon Y. Enteropathogenic Escherichia coli-induced macrophage inhibitory cytokine 1 mediates most cancers cell survival: an in vitro implication of infection-linked tumor dissemination. Oncogene. 2013;32:4960–9.
Amir I, Konikoff FM, Oppenheim M, Gophna U, Half EE. Gastric microbiota is altered in oesophagitis and Barrett’s oesophagus and additional modified by proton pump inhibitors. Environ Microbiol. 2014;16:2905–14.
Zaidi AH, Kelly LA, Kreft RE, Barlek M, Omstead AN, Matsui D, et al. Associations of microbiota and toll-like receptor signaling pathway in esophageal adenocarcinoma. BMC Most cancers. 2016;16:52.
Zhang R, Han D, Li L, Luo W, Liu J, Qian L. EphA5 silencing will increase the radiosensitivity of ESCC cells by way of ATM-dependent pathway. Most cancers Manag Res. 2020;12:9539–49.
Gillespie MR, Rai V, Agrawal S, Nandipati KC. The position of microbiota within the pathogenesis of esophageal adenocarcinoma. Biology. 2021;10:697.
Ouaknine Krief J, Helly de Tauriers P, Dumenil C, Neveux N, Dumoulin J, Giraud V, et al. Position of antibiotic use, plasma citrulline and blood microbiome in superior non-small cell lung most cancers sufferers handled with nivolumab. J Immunother Most cancers. 2019;7:176.
Dong Z, Chen B, Pan H, Wang D, Liu M, Yang Y, et al. Detection of microbial 16S rRNA gene within the serum of sufferers with gastric most cancers. Entrance Oncol. 2019;9:608.
Kohata Y, Nakahara Ok, Tanigawa T, Yamagami H, Shiba M, Watanabe T, et al. Rebamipide alters the esophageal microbiome and reduces the incidence of Barrett’s esophagus in a rat mannequin. Digestive Dis Sci. 2015;60:2654–61.
Kaakoush NO, Morris MJ. The oesophageal microbiome: an unexplored hyperlink in obesity-associated oesophageal adenocarcinoma. FEMS Microbiol Ecol. 2016;92.
Zhong L, Zhang X, Covasa M. Rising roles of lactic acid micro organism in safety towards colorectal most cancers. World J Gastroenterology: WJG. 2014;20:7878–86.
Gopalakrishnan V, Helmink BA, Spencer CN, Reuben A, Wargo JA. The affect of the intestine microbiome on most cancers, immunity, and most cancers immunotherapy. Most cancers Cell. 2018;33:570–80.
Legesse Bedada T, Feto TK, Awoke KS, Garedew AD, Yifat FT, Birri DJ. Probiotics for most cancers various prevention and therapy. Biomedicine Pharmacother. 2020;129:110409.
Somewhat IA, Bajpai VK, Ching LL, Majumder R, Nam G-J, Indugu N, et al. Impact of a bioactive product SEL001 from Lactobacillus sakei probio65 on intestine microbiota and its anti-colitis results in a TNBS-induced colitis mouse mannequin. Saudi J Biol Sci. 2020;27:261–70.
Kim S-Y, Shin J-S, Chung Ok-S, Han H-S, Lee H-H, Lee J-H, et al. Immunostimulatory results of reside Lactobacillus sakei K040706 on the CYP-induced immunosuppression mouse mannequin. Vitamins. 2020;12:E3573.
Ota A, Morita S, Matsuoka A, Shimokata T, Maeda O, Mitsuma A, et al. Detection of micro organism in blood circulation in sufferers receiving most cancers chemotherapy. Int J Clin Oncol. 2020;25:210–5.
Buc E, Dubois D, Sauvanet P, Raisch J, Delmas J, Darfeuille-Michaud A, et al. Excessive prevalence of mucosa-associated E. coli producing cyclomodulin and genotoxin in colon most cancers. PLoS ONE. 2013;8:e56964.
Fabbri A, Travaglione S, Ballan G, Loizzo S, Fiorentini C. The cytotoxic necrotizing issue 1 from E. Coli: a Janus toxin taking part in with most cancers regulators. Toxins. 2013;5:1462–74.
Pleguezuelos-Manzano C, Puschhof J, Rosendahl Huber A, van Hoeck A, Wooden HM, Nomburg J, et al. Mutational signature in colorectal most cancers brought on by genotoxic pks+ E. coli. Nature. 2020;580:269–73.
Fabbri A, Bracci L. Immunomodulatory properties of CNF1 toxin from E. coli: implications for colorectal carcinogenesis. Am J Most cancers Res. 2022;12:651–60.
Polimeno L, Barone M, Mosca A, Viggiani MT, Di Leo A, Debellis L, et al. Intestine microbiota imbalance is said to sporadic colorectal neoplasms. A Pilot Examine. Appl Sci. 2019;9:5491.
Castillo DJ, Rifkin RF, Cowan DA, Potgieter M. The wholesome human blood microbiome: truth or fiction? Entrance Cell Infect Microbiol. 2019;9:148.
